Maintenance Tyrosine Kinase Inhibitors Following Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia: A Center for International Blood and Marrow Transplant Research Study

Zachariah DeFilipp; Richard Ancheta; Ying Liu; Zhen-Huan Hu; Robert Peter Gale; David Snyder; Harry C Schouten; Matt Kalaycio; Gerhard C Hildebrandt; Celalettin Ustun; Andrew Daly; Siddhartha Ganguly; Yoshihiro Inamoto; Mark Litzow; Jeffrey Szer; Mary Lynn Savoie; Nasheed Hossain; Mohamed A Kharfan-Dabaja; Mehdi Hamadani; Ran Reshef; Ashish Bajel; Kirk R Schultz; Shahinaz Gadalla; Aaron Gerds; Jane Liesveld; Mark B Juckett; Rammurti Kamble; Shahrukh Hashmi; Hisham Abdel-Azim; Melhem Solh; Ulrike Bacher; Hillard Lazarus; Richard Olsson; Jean-Yves Cahn; Michael R Grunwald; Bipin N Savani; Jean Yared; Jacob M Rowe; Jan Cerny; Naeem A Chaudhri; Mahmoud Aljurf; Amer Beitinjaneh; Sachiko Seo; Taiga Nishihori; Jack W Hsu; Muthalagu Ramanathan; Edwin Alyea; Uday Popat; Ronald Sobecks; Wael Saber

doi:10.1016/j.bbmt.2019.10.017

Back

Maintenance Tyrosine Kinase Inhibitors Following Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia: A Center for International Blood and Marrow Transplant Research Study

Journal article

Open access

Peer reviewed

Maintenance Tyrosine Kinase Inhibitors Following Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia: A Center for International Blood and Marrow Transplant Research Study

Zachariah DeFilipp, Richard Ancheta, Ying Liu, Zhen-Huan Hu, Robert Peter Gale, David Snyder, Harry C Schouten, Matt Kalaycio, Gerhard C Hildebrandt, Celalettin Ustun, …

Biology of blood and marrow transplantation, Vol.26(3), pp.472-479

2020-03

DOI: https://doi.org/10.1016/j.bbmt.2019.10.017

PMID: 31669399

Abstract

Chronic myelogenous leukemia

Maintenance

Tyrosine kinase inhibitor

Allogeneic hematopoietic cell transplantation

•Maintenance tyrosine kinase inhibitor (TKI) therapy did not significantly impact outcomes of allogeneic hematopoietic cell transplantation (allo-HCT) performed to treat chronic myelogenous leukemia.•Results were not modified by the status of disease before transplantation.•The optimal approach to TKI therapy after allo-HCT remains undetermined. It remains unknown whether the administration of tyrosine kinase inhibitors (TKIs) targeting BCR-ABL1 after allogeneic hematopoietic cell transplantation (HCT) is associated with improved outcomes for patients with chronic myelogenous leukemia (CML). In this registry study, we analyzed clinical outcomes of 390 adult patients with CML who underwent transplantation between 2007 and 2014 and received maintenance TKI following HCT (n = 89) compared with no TKI maintenance (n = 301), as reported to the Center for International Blood and Marrow Transplant Research. All patients received TKI therapy before HCT. The majority of patients had a disease status of first chronic phase at HCT (n = 240; 62%). The study was conducted as a landmark analysis, excluding patients who died, relapsed, had chronic graft-versus-host disease, or were censored before day +100 following HCT. Of the 89 patients who received TKI maintenance, 77 (87%) received a single TKI and the other 12 (13%) received multiple sequential TKIs. The most common TKIs used for maintenance were dasatinib (n = 50), imatinib (n = 27), and nilotinib (n = 27). As measured from day +100, the adjusted estimates for 5-year relapse (maintenance, 35% versus no maintenance, 26%; P = .11), leukemia-free survival (maintenance, 42% versus no maintenance, 44%; P = .65), or overall survival (maintenance, 61% versus no maintenance, 57%; P = .61) did not differ significantly between patients receiving TKI maintenance or no maintenance. These results remained unchanged in multivariate analysis and were not modified by disease status before transplantation. In conclusion, our data from this day +100 landmark analysis do not demonstrate a significant impact of maintenance TKI therapy on clinical outcomes. The optimal approach to TKI administration in the post-transplantation setting in patients with CML remains undetermined.

Files and links (1)

url

https://doi.org/10.1016/j.bbmt.2019.10.017View

Published (Version of record) Open

Metrics

4 Record Views

18 Times Cited - Web of Science

See more details

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types: Domestic collaboration; International collaboration
Citation topics: 1 Clinical & Life Sciences; 1.103 Blood Disorders; 1.103.1126 Chronic Myeloid Leukemia
Web Of Science research areas: Hematology; Immunology; Transplantation
ESI research areas: Immunology

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

Source: InCites

Details

Title: Maintenance Tyrosine Kinase Inhibitors Following Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia: A Center for International Blood and Marrow Transplant Research Study
Creators: Zachariah DeFilipp - Blood and Marrow Transplant Program, Massachusetts General Hospital, Boston, Massachusetts
Richard Ancheta - Scripps Blood & Marrow Transplant Program, Scripps Green Hospital, La Jolla, California
Ying Liu - Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin
Zhen-Huan Hu - Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin
Robert Peter Gale - Hematology Research Centre, Division of Experimental Medicine, Department of Medicine, Imperial College London, London, United Kingdom
David Snyder - Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, California
Harry C Schouten - Department of Hematology, Academische Ziekenhuis, Maastricht, The Netherlands
Matt Kalaycio - Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, Ohio
Gerhard C Hildebrandt - Markey Cancer Center, University of Kentucky, Lexington, Kentucky
Celalettin Ustun - Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota Medical Center, Minneapolis, Minnesota
Andrew Daly - Tom Baker Cancer Centre, Calgary, Alberta, Canada
Siddhartha Ganguly - Division of Hematological Malignancy and Cellular Therapeutics, University of Kansas Health System, Kansas City, Kansas
Yoshihiro Inamoto - Division of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan
Mark Litzow - Division of Hematology and Transplant Center, Mayo Clinic Rochester, Rochester, Minnesota
Jeffrey Szer - Department Clinical Haematology and Bone Marrow Transplantation, Royal Melbourne Hospital, Victoria, Australia
Mary Lynn Savoie - Tom Baker Cancer Centre, Calgary, Alberta, Canada
Nasheed Hossain - Stanford Health Care, Stanford, California
Mohamed A Kharfan-Dabaja - Division of Hematology-Oncology, Blood and Marrow Transplantation Program, Mayo Clinic, Jacksonville, Florida
Mehdi Hamadani - Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin
Ran Reshef - Blood and Marrow Transplantation Program and Columbia Center for Translational Immunology, Columbia University Medical Center, New York, New York
Ashish Bajel - Department Clinical Haematology and Bone Marrow Transplantation, Royal Melbourne Hospital, Victoria, Australia
Kirk R Schultz - Department of Pediatric Hematology, Oncology and Bone Marrow Transplant, British Columbia's Children's Hospital, The University of British Columbia, Vancouver, BC, Canada
Shahinaz Gadalla - Division of Cancer Epidemiology & Genetics, NIH-NCI Clinical Genetics Branch, Rockville, Maryland
Aaron Gerds - Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, Ohio
Jane Liesveld - Department of Medicine, University of Rochester Medical Center, Rochester, New York
Mark B Juckett - Division of Hematology/Oncology/Bone Marrow Transplantation, Department of Medicine, University of Wisconsin Hospital and Clinics, Madison, Wisconsin
Rammurti Kamble - Division of Hematology and Oncology, Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas
Shahrukh Hashmi - Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota
Hisham Abdel-Azim - Division of Hematology, Oncology and Blood & Marrow Transplantation, Children's Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, California
Melhem Solh - The Blood and Marrow Transplant Group of Georgia, Northside Hospital, Atlanta, Georgia
Ulrike Bacher - Department of Hematology, Inselspital, Bern University Hospital, Switzerland
Hillard Lazarus - Seidman Cancer Center, University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, Ohio
Richard Olsson - Division of Therapeutic Immunology, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden
Jean-Yves Cahn - Department of Hematology, CHU Grenoble Alpes, Grenoble, France
Michael R Grunwald - Carolinas Medical Center Blumenthal Cancer Center Stem Cell Transplant Program, Levine Cancer Institute, Charlotte, North Carolina
Bipin N Savani - Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee
Jean Yared - Blood & Marrow Transplantation Program, Division of Hematology/Oncology, Department of Medicine, Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland
Jacob M Rowe - Department of Hematology, Shaare Zedek Medical Center, Jerusalem, Israel
Jan Cerny - Division of Hematology and Oncology, Department of Medicine, UMass Memorial Medical Center, Worcester, Massachusetts
Naeem A Chaudhri - Department of Oncology, Center, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia
Mahmoud Aljurf - Department of Oncology, Center, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia
Amer Beitinjaneh - Department of Medicine, University of Miami, Miami, Florida
Sachiko Seo - Department of Hematology & Oncology, National Cancer Research Center East, Chiba, Japan
Taiga Nishihori - Department of Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
Jack W Hsu - Division of Hematology & Oncology, Department of Medicine, Shands HealthCare and University of Florida, Gainesville, Florida
Muthalagu Ramanathan - Division of Hematology and Oncology, Department of Medicine, UMass Memorial Medical Center, Worcester, Massachusetts
Edwin Alyea - Center of Hematologic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
Uday Popat - Department of Stem Cell Transplantation and Cellular Therapy, University of Texas M.D. Anderson Cancer Center, Houston, Texas
Ronald Sobecks - Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, Ohio
Wael Saber - Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin
Publication Details: Biology of blood and marrow transplantation, Vol.26(3), pp.472-479
Publisher: Elsevier Inc
Academic Unit: Miller School of Medicine; UMMG Dept of Medicine - Hematology/Oncology
Language: English
Resource Type: Journal article
PMID: 31669399
Record Identifier: 991031597012402976